SEC Comment Letter for Vaxart, (VXRT) — Apr 21, 2026
Vaxart, Inc.
Date: April 21, 2026 · CIK: 0000072444 · Accession: 0000000000-26-004034
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295086
Letter
Re: Vaxart, Inc. Registration Statement on Form S-3 Filed April 16, 2026 File No. 333-295086 Dear Steven Lo:
April 21, 2026
Steven Lo Chief Executive Officer Vaxart, Inc. 310 Utah Avenue, Suite 150 South San Francisco, CA 94080
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Faith L. Charles, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 21, 2026 Steven Lo Chief Executive Officer Vaxart, Inc. 310 Utah Avenue, Suite 150 South San Francisco, CA 94080 Re: Vaxart, Inc. Registration Statement on Form S-3 Filed April 16, 2026 File No. 333-295086 Dear Steven Lo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Faith L. Charles, Esq. </TEXT> </DOCUMENT>